Truqap is a kinase inhibitor that actually works by blocking pathways that aid the cancer cells survive and expand, so lessens most cancers growth. Truqap is from a category of medicines called an AKT inhibitor. Truqap received FDA acceptance on November 17, 2023, soon after favourable outcomes within the CAPItello-291 https://semaglutide68912.qodsblog.com/34798534/considerations-to-know-about-capivasertib